

□ Signature: __

SPECIAL AUTHORIZATION REQUEST FORM

The Newfoundland and Labrador Prescription Drug Program (NLPDP) **Biologic Therapy for Inflammatory Bowel Disease**

Pharmaceutical Services

Department of Health and Community Services P.O. Box 8700, Confederation Bldg.

St. John's, NL A1B 4J6

Phone: Toll Free Line:

(709) 729-6507 1-888-222-0533

(709) 729-2851 Fax:

Patient Information		
Patlent Name	Date of Birth	NLPDP Drug Card/MCP Number
Address		Deticat Weight (I/O)
Address		Patient Weight (KG)
Diagnostic/Drug Information		
☐ Moderate or Severe Active Croh	n's Disease	
☐ Moderate or Severe Active Ulce		
□ Other		
Requested Drug Name and Dose:	☐ Initiation ☐	☐ Maintenance
Drug	Doco	Expected start date
Drug	D0Se	Expected start date
For Initiation/Baseline	For R	enewal/Maintenance
Crohn's Disease	Crohn's Disease	
□нві	□нві	
□CDAI	□CDAI	
		0.199
Ulcerative Colitis	Ulcerative Colitis	
☐ Partial Mayo		
Rectal Bleeding subscore	□Recta	i Bleeding Subscore
Date assessed	Date ass	sessed
	Medication Histor	
MEDICATION DOSE	DATE/DURATION	ОИТСОМЕ
5-ASA		□ Refractory
		□ Intolerant (describe)
Corticosteroid (Name)		□ Refractory
		□ Dependent
		□ Intolerant (describe)
Immunosuppressant (Name)		□ Refractory
		□ Intolerant (describe)
Define the series of affine the state of affine the state of		A described and the state of th
Refractory is defined as lack of effect at the		out recurrence or relapse within 3 months of
stopping steroid or needs 2 or more steroid		out recurrence or relapse within 3 months of
		traindications to treatments as defined in product
monographs. The nature of intolerance(s) n	nust be clearly document	ed.
Additional Comments:		
Prescriber Information/Requested b	-	
	License Number:	Phone Number: Fax Number:

_ Date: ____